GR3035941T3 - Vaccine adjuvants - Google Patents

Vaccine adjuvants

Info

Publication number
GR3035941T3
GR3035941T3 GR20010400796T GR20010400796T GR3035941T3 GR 3035941 T3 GR3035941 T3 GR 3035941T3 GR 20010400796 T GR20010400796 T GR 20010400796T GR 20010400796 T GR20010400796 T GR 20010400796T GR 3035941 T3 GR3035941 T3 GR 3035941T3
Authority
GR
Greece
Prior art keywords
adjuvants
vaccine
vaccine adjuvants
sulpholipid
polysaccharide
Prior art date
Application number
GR20010400796T
Other languages
English (en)
Inventor
Luuk Hilgers
Original Assignee
Dimminaco Ag Sa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3888560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3035941(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dimminaco Ag Sa Ltd filed Critical Dimminaco Ag Sa Ltd
Publication of GR3035941T3 publication Critical patent/GR3035941T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR20010400796T 1994-12-27 2001-05-28 Vaccine adjuvants GR3035941T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9401174A BE1008978A5 (fr) 1994-12-27 1994-12-27 Adjuvants pour vaccins.
PCT/BE1995/000119 WO1996020008A1 (fr) 1994-12-27 1995-12-21 Adjuvants pour vaccins

Publications (1)

Publication Number Publication Date
GR3035941T3 true GR3035941T3 (en) 2001-08-31

Family

ID=3888560

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400796T GR3035941T3 (en) 1994-12-27 2001-05-28 Vaccine adjuvants

Country Status (17)

Country Link
US (2) US6328965B1 (el)
EP (2) EP0800539B1 (el)
JP (2) JP4087900B2 (el)
CN (2) CN1132630C (el)
AT (2) ATE248863T1 (el)
AU (2) AU713997B2 (el)
BE (1) BE1008978A5 (el)
BR (2) BR9510223A (el)
CA (2) CA2208790C (el)
DE (2) DE69531699T2 (el)
DK (2) DK0800539T3 (el)
ES (2) ES2155540T3 (el)
GR (1) GR3035941T3 (el)
MX (1) MX9704822A (el)
PT (2) PT800539E (el)
SI (1) SI0800539T1 (el)
WO (2) WO1996020222A1 (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6645495B1 (en) * 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
EP1104767A1 (en) * 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
AT408150B (de) * 2000-04-14 2001-09-25 Oesterr Forsch Seibersdorf Verfahren zur immobilisierung eines analyten an einer festen oberfläche
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2825714B1 (fr) * 2001-06-08 2005-03-25 Seppic Sa Nouvelle utilisation de complexes d'inclusion de cyclodestrine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003086283A2 (en) * 2002-04-09 2003-10-23 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
AU2006318216C1 (en) 2005-11-28 2012-02-16 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
EP2217271B1 (en) 2007-11-06 2016-05-04 Zoetis Services LLC Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
EP2062594A1 (en) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
EP2397484A1 (en) 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharide derivates, and their use as adjuvants
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN101972477B (zh) * 2010-10-21 2012-09-26 中国医学科学院医学生物学研究所 磷酸锌疫苗佐剂
DK2654784T3 (en) 2010-12-22 2017-02-13 Wyeth Llc STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
EP3363806B1 (en) 2012-12-20 2022-11-16 Pfizer Inc. Glycoconjugation process
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN105579060B (zh) 2013-09-25 2021-03-16 硕腾服务有限责任公司 Pcv2b趋异株疫苗组合物以及使用方法
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
CN104086676B (zh) * 2014-07-18 2017-01-25 江苏省农业科学院 一种环糊精酯化衍生物、制备方法及其应用
PL3193923T3 (pl) * 2014-07-24 2020-03-31 Litevax B.V. Adiuwanty
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20220774A1 (es) 2015-05-04 2022-05-16 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN106928378A (zh) * 2017-03-29 2017-07-07 中国药科大学 一种十二酰基‑β‑环糊精的制备方法和用于色氨酸手性拆分的聚砜膜的制备方法
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
EP3846853A1 (en) 2018-09-04 2021-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal nanoparticles and use thereof against influenza virus
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565887A (en) * 1968-05-15 1971-02-23 Corn Products Co Unsaturated and long chain esters of cyclodextrin
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
IT1242214B (it) * 1990-11-13 1994-03-03 Emo Chiellini Derivati polifunzionali delle ciclodestrine
JP2556236B2 (ja) * 1991-08-29 1996-11-20 田辺製薬株式会社 β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
JP3723231B2 (ja) * 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
DE4220734A1 (de) * 1992-06-25 1994-01-05 Puetter Medice Chem Pharm Lipophile Cyclodextrinpolymere
US5464827A (en) * 1994-06-20 1995-11-07 American Home Products Corporation Esterified polyanionic cyclodextrins as smooth muscle cell proliferation inhibitors
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.

Also Published As

Publication number Publication date
CN1175264A (zh) 1998-03-04
MX9704824A (es) 1998-06-30
US6328965B1 (en) 2001-12-11
WO1996020008A1 (fr) 1996-07-04
CA2208790A1 (en) 1996-07-04
ES2155540T3 (es) 2001-05-16
BE1008978A5 (fr) 1996-10-01
DE69520376D1 (de) 2001-04-19
DK0814836T3 (da) 2001-04-17
JP4087900B2 (ja) 2008-05-21
MX9704822A (es) 1998-05-31
AU713997B2 (en) 1999-12-16
CN1132630C (zh) 2003-12-31
CA2208790C (en) 2012-01-31
DE69531699T2 (de) 2004-07-08
AU4324896A (en) 1996-07-19
CA2208849C (en) 2006-10-10
DE69531699D1 (de) 2003-10-09
PT800539E (pt) 2004-01-30
SI0800539T1 (en) 2003-12-31
EP0814836B1 (fr) 2001-03-14
CN1171052A (zh) 1998-01-21
EP0814836A1 (fr) 1998-01-07
EP0800539B1 (en) 2003-09-03
PT814836E (pt) 2001-07-31
EP0800539A1 (en) 1997-10-15
DE69520376T2 (de) 2001-08-09
BR9510263A (pt) 1997-11-04
JPH10511997A (ja) 1998-11-17
AU709104B2 (en) 1999-08-19
JPH11502192A (ja) 1999-02-23
DK0800539T3 (da) 2003-12-08
CN1109049C (zh) 2003-05-21
AU4324996A (en) 1996-07-19
JP3927235B2 (ja) 2007-06-06
ATE248863T1 (de) 2003-09-15
US6165995A (en) 2000-12-26
BR9510223A (pt) 1997-12-30
ES2204969T3 (es) 2004-05-01
CA2208849A1 (en) 1996-07-04
WO1996020222A1 (en) 1996-07-04
ATE199644T1 (de) 2001-03-15

Similar Documents

Publication Publication Date Title
GR3035941T3 (en) Vaccine adjuvants
ATE410183T1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
ATE196737T1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
DE69529684D1 (en) Adjuvans für impfstoff
GB9817052D0 (en) Vaccine
DK55891D0 (da) Matrix med immunomodulerende virkning
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
BR9106205A (pt) Dispositivo para implantacao em hospedeiro,processo de implantacao,dispositivo implantado,e recipiente de imunoisolamento
NO932102L (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
ES2044849T3 (es) Un procedimiento para preparar un glicosido de flavona.
OA09800A (en) Vaccine compositions containing liposomes.
NL300400I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
ATE220687T1 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
TW340873B (en) Chicken anaemia agent vaccine
AU1362895A (en) Pasteurella multocida toxoid vaccines
CA2090701A1 (en) Solubilization of proteins in active forms
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
GR3019525T3 (en) Neuraminidase and galactose oxidase as vaccine adjuvant
GB9303681D0 (en) Vaccines
FI973831A0 (fi) Menetelmä spirolaksiinin ja spirolaksiinimetyylieetterin valmistamiseksi